The current study aimed to identify the radiosensitizing effect of celecoxib, a selective
cyclooxygenase-2 (COX-2) inhibitor, in combination with radiotherapy in non-small-cell lung …

BACKGROUND: Radiosensitivity by blocking the epidermal growth factor receptor and
cyclooxygenase-2 pathways with erlotinib and celecoxib in A549 human lung cancer cell …

Radiotherapy resistance is an enduring major setback in lung cancer therapy, and is
responsible for a large proportion of treatment failures. In previous years, cyclooxygenase‑2 …

Purpose Radioresistance is highly correlated with radiotherapy failure in clinical cancer
treatment. In the current study, we sought to examine the efficacy of Celecoxib and Afatinib …

Background: Previous work has proposed that celecoxib may be able to enhance the effects
of radiotherapy. However, the underlying mechanism of this activity has not yet been …

To characterize the radiation-enhancing effects on human cancer cells and underlying
mechanisms of celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, and to ascertain …

Purpose: To characterize the radiation-enhancing effects and underlying mechanisms of
combined treatment with celecoxib, a cyclooxygenase-2 selective inhibitor, and gefitinib, an …

Abstract Different cyclooxygenase (COX)-2 inhibitors were known to cause different cell
cycle changes. We investigated whether this different effect on cell cycle change was due to …

To investigate genes regulated by COX-2 or a COX-2 specific inhibitor, celecoxib, in
irradiated cancer cells, we analyzed changes in gene expression using complementary …

It has been reported that celecoxib, a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-
inflammatory drug (NSAID), regulates the radiosensitivity of several cancer cells. BCCIP …